nPhase lands $30M Series D for AI-native clinical data platform
What's the deal? nPhase has closed a $30 million Series D round led by Viking Global InvestorsDealroom has a profile for this one. Try Dealroom → to expand its AI-native clinical data platform for pharmaceutical sponsors. Viking manages more than $54 billion across public and private investments.
Why now? The raise is nPhase's first equity financing since 2017 — nearly a decade without outside equity. It follows the September launch of nPhase.aiDealroom has a profile for this one. Try Dealroom →, which pairs the company's Unified Data Management System (UDMS) and Statistical Computing Environment (SCE) to connect clinical data from study startup through regulatory submission.
What's the endgame? nPhase wants to turn fragmented clinical data into one governed, AI-ready foundation. It says its platform aggregates data continuously, validates it in near real time, and compresses submission workflows that typically take four or more months into weeks.
What does the money do? The funding will scale nPhase's enterprise business and expand its agentic AI capabilities, where autonomous agents handle high-volume tasks such as flagging data discrepancies and drafting statistical programming while humans keep decision authority.
“We've built the unified, governed data foundation that makes AI possible across the clinical data lifecycle,” said chief executive officer Scott Climes.
Levi Malik, a principal at Viking Global Investors, said nPhase combines “an established foundation in clinical research, deep understanding of regulatory requirements, and a clear vision for enterprise-scale AI.”
What could go wrong? The round funds ambition, not proof. The announcement does not establish customer adoption or validate the platform's performance claims.
The signal: Capital is flowing into AI for clinical development — QuantHealth raised $45 million in August for trial simulation, and Oracle, AstraZeneca, and IQVIA have made related moves. Those target different parts of the process, but together they point to rising demand for connected data as the base layer for AI in drug development.
Read more: morningstar.com
Image credit: Generated with Gemini
